药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

已收盘 10-20 16:08:20

75.850

+1.400

+1.88%

最高77.750	最低73.700	成交量388.16万
今开74.750	昨收74.450	日振幅5.44%
总市值963.30亿	流通市值963.30亿	总股本12.70亿
成交额2.93亿	换手率0.31%	流通股本12.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":75.85,"timestamp":1792483700003,"preClose":74.45,"halted":0,"volume":3881644,"delay":0,"changeRate":0.018804566823371276,"floatShares":1270000000,"shares":1270000000,"eps":1.119999,"marketStatus":"已收盘","change":1.4,"latestTime":"10-20 16:08:20","open":74.75,"high":77.75,"low":73.7,"amount":293158658,"amplitude":0.054399,"askPrice":75.85,"askSize":500,"bidPrice":75.75,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.393408732,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792546200000},"marketStatusCode":5,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":74.45,"openAndCloseTimeList":[[1792459800000,1792468800000],[1792472400000,1792483200000]],"volumeRatio":0.546756,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2676665575","title":"创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665575","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665575?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:23","pubTimestamp":1792466598,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念强势，截至发稿，乐普生物 涨8.81%，翰森制药涨7.06%，药明生物涨6.74%，晶泰控股涨4.56%，康诺亚-B涨4.70%，亚盛医药涨4.30%，恒瑞医药涨4.16%，药明合联涨3.96%，云顶新耀涨3.89%，和黄医药涨3.68%，中国生物制药涨3.24%，石药集团涨3.16%，科伦博泰生物涨3.14%，诺诚健华涨3.08%。消息面上，据人民财讯，10月20日，国家发展改革委召开10月份新闻发布会，会上提到，我国前三季度创新药对外技术授权约1300亿美元，接近去年全年。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","BK1576","06990","06978","02157","LU0128522744.USD","LU0359201885.HKD","LU0979878070.USD","LU0417516738.SGD","LU0052750758.USD","LU0211977185.USD","LU1152091754.HKD","KURE","02162","02228","LU0196878994.USD","LU1008478684.HKD","MEDX","IBBQ","02269","LU0417516902.SGD","06855","BK1589","LU0072913022.USD","LU1794554557.SGD","LU0043850808.USD","BK1161","159992","02268","LU1226288170.HKD","BK1521","LU2488822045.USD","LU2543165471.USD","01093","LU0348827113.USD","LU1993786604.SGD","LNGR","LU1188198961.HKD","03692","01952","01276","00013","01177","BK1610","LU1720050803.USD","IE0008369823.USD","LU2476274720.SGD","LU1242518857.USD","LU0588546209.SGD","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175200909","title":"异动解读｜药明合联盘中上涨3.63%，ADC与CXO景气预期提振板块","url":"https://stock-news.laohu8.com/highlight/detail?id=1175200909","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175200909?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:57","pubTimestamp":1792465020,"startTime":"0","endTime":"0","summary":"10月20日，药明合联盘中上涨3.63%，报77.15港元/股，成交额1.49亿港元。消息面上，ADC产业链再获关注，翰森制药当日因与罗氏再签ADC战略合作大单而走强，叠加机构近期继续看好创新药与CXO龙头，带动药明合联所在板块情绪回暖。背景上看，公司所处ADC CRDMO赛道景气度较高，其中其上半年综合收益达37.014亿元人民币，按固定汇率同比增长41.5%；同时，机构此前提到港股及A股CXO收入分别增长29.2%和25.3%，行业订单需求处于高位，强化了市场对龙头公司的业绩预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联盘中上扬，ADC与CXO景气预期提振板块","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109072607","title":"创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109072607","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109072607?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:51","pubTimestamp":1792115499,"startTime":"0","endTime":"0","summary":"港股创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%，百济神州涨超6%，再鼎医药涨近5%，药明合联、药明生物涨超4%，药明康德涨近4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","01548","06160","02162","01952","02359","02268","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137630417","title":"异动解读｜药明合联盘中上涨3.09%，医药外包板块反弹带动回升","url":"https://stock-news.laohu8.com/highlight/detail?id=1137630417","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137630417?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:39","pubTimestamp":1792114780,"startTime":"0","endTime":"0","summary":"10月16日，药明合联盘中上涨3.09%，报76.5港元/股，成交额2.01亿港元。消息面上，此前连续回调的CXO及生命科学工具与服务板块出现反弹，带动公司股价回升，板块联动成为本次异动的主要驱动。近期公司股价曾因医药外包与AI制药相关板块承压而连续走弱，但机构此前给予买入评级、目标价97.9港元，并提到无锡生产设施首次FDA检查预期是中长期催化。在当天交易中，同板块个股普遍上涨，药明生物涨3.31%，药明康德涨2.49%，晶泰控股涨3.82%，显示情绪修复对盘面形成支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联盘中上涨，医药外包反弹带动回升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126484265","title":"异动解读｜药明合联盘中下跌3.31%，医药外包板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1126484265","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126484265?lang=zh_cn&edition=full","pubTime":"2026-10-15 14:31","pubTimestamp":1792045900,"startTime":"0","endTime":"0","summary":"10月15日，药明合联盘中下跌3.31%，报74.5港元/股，成交额3.21亿港元。消息面上，近期生命科学工具和服务板块整体走弱，同业股价普遍回调，继续压制药明合联盘面表现。此前公司虽获机构给予买入评级、目标价97.9港元，且无锡生产设施首次FDA检查预期被视为长期催化，但最新一轮交易中板块情绪仍占主导。同行中，金斯瑞生物-一千跌9.65%，英矽智能跌8.51%，晶泰控股跌4.89%，药明生物跌2.29%，药明康德跌0.99%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联盘中下挫，医药外包板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141600517","title":"异动解读｜药明合联盘中下跌3.02%，CXO与AI制药板块回调拖累","url":"https://stock-news.laohu8.com/highlight/detail?id=1141600517","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141600517?lang=zh_cn&edition=full","pubTime":"2026-10-14 13:47","pubTimestamp":1791956856,"startTime":"0","endTime":"0","summary":"10月14日，药明合联盘中下跌3.02%，报77.2港元，成交额1.42亿港元。近期消息面显示，港股医药外包与AI制药相关板块连续承压，药明合联此前已在10月13日随CXO概念重挫，一度跌近8%，板块回调成为本次异动的直接背景。从基本面看，公司上半年营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；但短线市场交易重心仍偏向板块风险偏好波动，而非业绩兑现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联随CXO板块回调，短线承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150879266","title":"异动解读｜药明合联盘中下跌4.24%，医药外包板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1150879266","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150879266?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:38","pubTimestamp":1791855524,"startTime":"0","endTime":"0","summary":"10月13日，药明合联盘中下跌4.24%，报80.65港元/股，成交额3177.57万港元。消息面上，生命科学工具和服务板块整体走弱，同业股价普遍回调，拖累药明合联表现。药明合联所在的生命科学工具和服务行业中，金斯瑞生物科技跌10.54%，英矽智能跌5.66%，晶泰控股跌4.50%，药明生物跌2.94%，药明康德跌1.73%。此前高盛给予公司买入评级，目标价97.9港元，并指出无锡生产设施即将迎来首次FDA检查，但短期板块情绪仍主导盘面走势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联股价承压，医药外包板块集体走弱","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157830362","title":"港股创新药概念股集体走低，华昊中天医药-B跌超11%、金斯瑞生物科技跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157830362","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157830362?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:38","pubTimestamp":1791855517,"startTime":"0","endTime":"0","summary":"10月13日，港股创新药概念股集体走低，$华昊中天医药-B(02563)$跌超11%，$金斯瑞生物科技(01548)$跌超10%，$药明合联(02268)$、$晶泰控股(02228)$跌超4%，$药明生物(02269)$、$歌礼制药-B(01672)$跌超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423091.SGD","BK1141","HK0000306685.HKD","KCAI","LU0327786744.USD","02269","LU1242518931.SGD","LU0588546209.SGD","KURE","LU1794554557.SGD","LU0856984785.SGD","LU2476274308.USD","LU0823426480.USD","IBBQ","LU1242518857.USD","LU2778985437.USD","VXUS","LU0823426308.USD","BK1161","LU0244354667.USD","02563","01477","LU0516422440.USD","LU1880383366.USD","LNGR","01548","HK0000320264.USD","HK0000320223.HKD","LU0540923850.HKD","LU2488822045.USD","BK1589","LU0043850808.USD","01672","LU0029874061.USD","LU0359202008.SGD","IE00B0JY6N72.USD","LU0307460666.USD","LU2476274720.SGD","LU0708995153.HKD","09939","BK4585","LU0417516738.SGD","LU0979878070.USD","LU0819121731.USD","LU0052750758.USD","BK1521","BK4588","LU0128526141.USD","LU0516422952.EUR","BK1583","LU0348825331.USD","LU0456827905.SGD","BK1515","BK1576","LU0348827113.USD","LU0140636845.USD","LU0326950275.SGD","LU0029874905.USD","BK1610","LU2039709279.SGD","SG9999002463.SGD","LU0417516902.SGD","LU0211977185.USD","LU1720050803.USD","LU0572944931.SGD","LU0463099449.HKD","LU1188198961.HKD","LU0320764599.SGD","LU0516423174.USD","LU0228659784.USD","LU0634319403.HKD","LU0456846285.SGD","LU0320764243.SGD","LU0039217434.USD","LU0828237510.HKD","HK0000306701.USD","06978","LU1831875114.USD","LU0128522744.USD","LU0051755006.USD","LU0348735423.USD","MEDX","02268","LU0561508036.HKD","LU0181495838.USD","LU0516422366.SGD","LU0359201612.USD","SG9999002562.SGD","LU1688375341.USD","02228","SG9999014674.SGD","LU0708995583.HKD","BK1574","LU3063872942.SGD","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160021299","title":"异动解读｜药明合联盘中上涨3.17%，医药外包板块分化中走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1160021299","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160021299?lang=zh_cn&edition=full","pubTime":"2026-10-12 10:53","pubTimestamp":1791773612,"startTime":"0","endTime":"0","summary":"10月12日，药明合联盘中上涨3.17%，报84.7港元，成交额1.28亿港元。此前高盛给予公司“买入”评级，目标价97.9港元，并指出无锡生产设施即将迎来首次FDA检查，商业化生产能力验证成为长期能见度关键催化剂。公司2026年上半年营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%，基本面保持稳健。在此基础上，机构评级与商业化里程碑预期构成短期催化，推动股价逆势走强。药明合联生物技术有限公司是一家主要从事提供抗体偶联药物及其他生物偶联药物的全面合同研究、开发及制造组织服务的投资控股公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联上涨，FDA检查催化商业化预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674188261","title":"生物医药板块继续回调 恒生生物科技指数跌2.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674188261","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674188261?lang=zh_cn&edition=full","pubTime":"2026-10-09 10:17","pubTimestamp":1791512279,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块继续回调，恒生生物科技指数跌2.31%，恒生医疗保健指数跌2.09%。个股方面，复宏汉霖（02696）跌4.84%，药明康德（02359）跌3.92%，药明合联（02268）跌3.47%，泰格医药（03347）跌3.35%，诺诚健华（09969）跌3.27%，药明生物（02269）跌3.33%，金斯瑞生物科技（01548）跌3.10%，康诺亚-B（02162）跌2.58%，百济神州（06160）跌2.44%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","399441","LU0181495838.USD","LU2488822045.USD","02268","LU1880383366.USD","LU2778985437.USD","SG9999002463.SGD","LU0856984785.SGD","LU0348825331.USD","LU0417516738.SGD","LU0359202008.SGD","LU2045819591.USD","02162","BK1521","BK4588","LU1688375341.USD","IE00B0JY6N72.USD","02359","LU0320764243.SGD","BK1161","LU0540923850.HKD","LU2039709279.SGD","SG9999014674.SGD","HK0000320264.USD","LU0417516902.SGD","BK1141","03347","KURE","XBI","LU0463099449.HKD","02269","BK4581","01548","LU1251922891.USD","LU0561508036.HKD","LU0516422440.USD","09969","LU0327786744.USD","LU2242644610.SGD","06160","BK1576","LU2125910500.SGD","LU1831875114.USD","161726","HK0000306685.HKD","LU0588546209.SGD","LU0320764599.SGD","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158084492","title":"异动解读｜药明合联盘中下跌3.47%，医药外包板块普遍承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1158084492","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158084492?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:38","pubTimestamp":1791509885,"startTime":"0","endTime":"0","summary":"10月9日，药明合联盘中下跌3.47%，报79.35港元/股，成交额9611.33万港元。消息面上，生命科学工具和服务板块整体走弱，同业股价普遍回调，拖累药明合联表现。药明合联所在的生命科学工具和服务行业中，药明生物跌3.51%，金斯瑞生物科技涨0.93%，药明康德跌1.91%，英矽智能跌2.16%，晶泰控股跌3.43%。药明合联生物技术有限公司是一家主要从事提供抗体偶联药物及其他生物偶联药物的全面合同研究、开发及制造组织服务的投资控股公司。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联随板块走弱，盘中下跌承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674892318","title":"【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892318","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674892318?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:38","pubTimestamp":1791506310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，多家创新药企业将于10月下旬ESMO公布重要临床数据。ESMO是欧洲最具盛名和影响力的肿瘤学会议，LBA是最高级别的研究成果展示，因此ESMO公布的LBA在医药行业广受关注。中国企业入选的LBA中，有四项入选最高级别的主席研讨会。该机构认为，以上情况表明中国创新药研发能力在海外广受认可，因此创新药板块值得继续关注。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","06978","LU1008478684.HKD","SG9999002463.SGD","IE00BZ08YR35.GBP","IE0008369823.USD","LU1242518931.SGD","02268","01177","02359","BK1521","CXO","MEDX","BK1191","WX","02269","LU0067412154.USD","LU1960683339.HKD","IBBQ","LU1831875114.USD","LU2399975544.HKD","IE00B5MMRT66.SGD","06821","01093","09926","LU0348783233.USD","LU0348767384.USD","LU0348827113.USD","LU0307460666.USD","LU0327786744.USD","LU0314109678.HKD","159992","00013","LU2097828557.USD","LU0572944931.SGD","LU2488822045.USD","LU0561508036.HKD","KCE","KURE","LNGR","01801","BK1500","LU0708995153.HKD","LU0823426308.USD","LU2125910500.SGD","LU1688375341.USD","LU0320764599.SGD","LU2097828714.EUR","LU0149534421.HKD","LU0029874905.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2673064659","title":"生物医药板块大幅回调 恒生生物科技指数跌3.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673064659","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673064659?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:35","pubTimestamp":1791336927,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块大幅回调，截至发稿，恒生生物科技指数跌3.15%，恒生医疗保健指数跌2.73%，万得港股中国创新药指数跌2.39%。个股方面，金斯瑞生物科技（01548）跌14.81%，再鼎医药（09688）跌4.47%，药明合联（02268）跌3.68%，药明生物（02269）跌2.50%，百济神州（06160）跌1.18%，诺诚健华（09969）跌1.43%，康诺亚-B（02162）跌1.32%，康方生物（09926）跌1.45%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","06160","LU0456827905.SGD","SG9999002562.SGD","LU0359202008.SGD","LU1794554557.SGD","LU0456846285.SGD","LU0561508036.HKD","LU0572944931.SGD","09926","KURE","02269","SG9999002463.SGD","LU0348766576.USD","LU0348784397.USD","09688","LU1880383366.USD","LU0348825331.USD","LU3063872942.SGD","LU0211977185.USD","LU0228659784.USD","LU1242518931.SGD","XBI","IE00B543WZ88.USD","LU1720050803.USD","09969","161726","LU0244354667.USD","BK1141","LU2488822045.USD","BK1161","LU0856984785.SGD","LU0417516738.SGD","LU1242518857.USD","LU0320764243.SGD","BK1574","BK1521","LU0052750758.USD","LU0828237510.HKD","LU0320764599.SGD","SG9999014674.SGD","01548","IE00B0JY6N72.USD","399441","02268","BK4588","LU0516423174.USD","LU0588546209.SGD","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116643115","title":"异动解读｜药明合联盘中下跌3.38%，医药外包板块普遍承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1116643115","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116643115?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:32","pubTimestamp":1791336734,"startTime":"0","endTime":"0","summary":"10月7日，药明合联盘中下跌3.38%，报81.1港元/股，成交额397.01万港元。消息面上，生命科学工具和服务板块整体走弱，同业股价普遍回调，拖累药明合联表现。药明合联所在的生命科学工具和服务行业中，药明生物跌2.42%，金斯瑞生物科技跌14.45%，英矽智能跌6.49%，药明康德跌1.1%，晶泰控股跌5.42%。药明合联生物技术有限公司是一家主要从事提供抗体偶联药物及其他生物偶联药物的全面合同研究、开发及制造组织服务的投资控股公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157950213","title":"药明合联公布9月股份变动月报表，股本增至1,270,498,306股","url":"https://stock-news.laohu8.com/highlight/detail?id=1157950213","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157950213?lang=zh_cn&edition=full","pubTime":"2026-10-06 17:16","pubTimestamp":1791278193,"startTime":"0","endTime":"0","summary":"药明合联于2026年10月6日发布了截至2026年9月30日的股份变动月报表。公告显示，公司法定注册股本维持10,000,000,000股，面值0.00005美元，对应法定股本总额500,000美元，本月无增减变动。截至9月底，普通股已发行股份由上月末的1,268,295,784股增加至1,270,498,306股，增幅为2,202,522股。公司另披露了2024年股份计划下可能发行的股份总数为15,482,026股，本月无实质性新增发行或转让。公司声明已遵守香港联交所《上市规则》及其他相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673035134","title":"小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673035134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673035134?lang=zh_cn&edition=full","pubTime":"2026-10-06 11:32","pubTimestamp":1791257520,"startTime":"0","endTime":"0","summary":"另外，该行预期本轮加息周期将于12月再加息一次后结束，而非延续至明年的长期紧缩，因此对利率上升影响中国医疗健康估值并不太担心，并继续看好生物科技及CXO子板块。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159837","JPMO","03696","TFNS","LNGR","01548","XBI","LABU","IYF","TRUF","SYNB","159760","WX","IXJ","02269","LU0345769128.USD","IEIH","FTXO","XLV","IE0034235295.USD","JPO","IXG","MEDX","02268","FNCL","06990","KURE","LU1670627923.USD","AGNG","KBWB","LU0976567544.SGD","HBImain","LU0345769631.USD","LU0708995153.HKD","XLF","LU1974910355.USD","02359","UYG","IBBJ","LU0572944931.SGD","IYG","XLBI","GDOC","PEX","VFH","EQRR","IE00BKDWB100.SGD","VHT","CXO","LU2168564065.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194236114","title":"异动解读｜药明合联盘中上涨3.02%，报83.60港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194236114","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194236114?lang=zh_cn&edition=full","pubTime":"2026-10-06 10:15","pubTimestamp":1791252936,"startTime":"0","endTime":"0","summary":"10月6日，药明合联盘中上涨3.02%，报83.60港元/股，成交额1991.57万港元。药明合联生物技术有限公司是一家主要从事提供抗体偶联药物及其他生物偶联药物的全面合同研究、开发及制造组织服务的投资控股公司。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185667589","title":"异动解读｜药明合联盘中下跌3.66%，大股东减持余波未消叠加生命科学板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1185667589","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185667589?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:41","pubTimestamp":1790905291,"startTime":"0","endTime":"0","summary":"10月2日，药明合联盘中下跌3.66%，报78.2港元，成交额2830.05万港元。消息面上，药明康德8月底通过大宗交易出售药明合联5352.4万股，持股比例由18.36%降至14.14%，涉资约39.2亿港元，大股东集中减持对市场情绪的压制效应仍在持续发酵。板块方面，生命科学工具和服务行业今日整体走弱，同业个股中英矽智能跌6.32%，晶泰控股跌5.56%，金斯瑞生物科技跌4.1%，药明康德跌3.35%，药明生物跌3.21%，板块系统性下行进一步放大个股跌幅。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联盘中走低，大股东减持余波未消","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222418","title":"创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222418","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222418?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:35","pubTimestamp":1790735739,"startTime":"0","endTime":"0","summary":"金吾财讯  | 创新药概念普涨，截至发稿，金斯瑞生物科技 涨10.10%，石药集团涨6.07%，云顶新耀涨5.79%，恒瑞医药涨5.18%，药明合联涨4.48%，晶泰控股涨4.06%，乐普生物涨3.52%，药明生物涨3.46%。消息面上，开源证券表示，整体上，持续看好创新药及其产业链及AI、脑机接口、生物制造等国家战略新兴产业。后续可重点跟踪ESMO临床数据、三季度订单及业绩验证和政策细则落地，积极把握优质创新药、CXO及生命科学上游调整后的配置机会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992823","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874905.USD","BK1610","BK1141","LU1807302812.USD","LU1880383366.USD","01276","LU0181495838.USD","LU1188198961.HKD","BK1574","IE00B0JY6N72.USD","LU0359201885.HKD","01093","LU0880133367.SGD","LU0348827113.USD","LU1226288170.HKD","MEDX","LU0540923850.HKD","LU1242518931.SGD","HK0000306701.USD","LU0140636845.USD","LU0823426480.USD","LNGR","02228","02157","LU1008478684.HKD","LU0039217434.USD","02268","IBBQ","IE00BZ08YT58.USD","LU1328277881.USD","LU0307460666.USD","LU0708995153.HKD","159992","01548","KURE","LU0128522744.USD","IE00BZ08YR35.GBP","LU0072913022.USD","01952","LU1813983027.USD","02269","06978","BK1521","LU0516422366.SGD","LU1242518857.USD","BK1161","BK1515","LU1688375341.USD","BK1589","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167325366","title":"异动解读｜药明合联盘中上涨3.01%，板块集体反弹叠加对外投资扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=1167325366","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167325366?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:35","pubTimestamp":1790732124,"startTime":"0","endTime":"0","summary":"9月30日，药明合联盘中上涨3.01%，报80.45港元，成交额1888.11万港元。消息面上，公司新增一起对外投资，以60.67%的持股比例投资东曜药业股份有限公司，进一步拓展ADC相关CDMO业务版图。板块方面，生命科学工具和服务行业今日集体走强，此前连续承压的板块迎来反弹，同业个股金斯瑞生物科技涨5.51%，英矽智能涨3.70%，药明生物涨2.24%，药明康德涨1.64%，板块联动共振提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联上涨，对外投资拓展ADC版图","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.0932},{"period":"1month","weight":-0.0053},{"period":"3month","weight":0.3968},{"period":"6month","weight":0.2336},{"period":"1year","weight":0.0659},{"period":"ytd","weight":0.2255}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.144701},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024159},{"month":3,"riseRate":0.666667,"avgChangeRate":0.102712},{"month":4,"riseRate":0.666667,"avgChangeRate":0.010649},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.091782},{"month":6,"riseRate":1,"avgChangeRate":0.069902},{"month":7,"riseRate":0.666667,"avgChangeRate":0.109892},{"month":8,"riseRate":0.666667,"avgChangeRate":0.150478},{"month":9,"riseRate":1,"avgChangeRate":0.240082},{"month":10,"riseRate":0,"avgChangeRate":-0.047883},{"month":11,"riseRate":0.5,"avgChangeRate":0.032073},{"month":12,"riseRate":0.666667,"avgChangeRate":0.053198}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}